Marshall Wace, LLP Vaxcyte, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $1.65 Million - $2.31 Million	-36,490 Reduced 28.58%	91,198 $5.73 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $19.4 Million - $22.4 Million	-422,678 Reduced 76.8%	127,688 $6.51 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $7.37 Million - $11.5 Million	212,611 Added 62.95%	550,366 $27.5 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $549,671 - $715,316	15,155 Added 4.7%	337,755 $12.7 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $6.64 Million - $15.5 Million	322,600 New	322,600 $15.5 Million
Q1 2021 May 17, 2021	SELL	$18.66 - $29.16 $269,189 - $420,662	-14,426 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$26.57 - $51.74 $239,847 - $467,056	-9,027 Reduced 38.49%	14,426 $383,000
Q3 2020 Nov 16, 2020	BUY	$26.5 - $55.4 $621,504 - $1.3 Million	23,453 New	23,453 $1.16 Million

354

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.33B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.